Clinical Trials Browser

Completed × Has announcements × Androgen Antagonists × Clear all

NCT02799602 2025-12-04

ARASENS

Phase 3 Completed

1,306 enrolled 25 charts 2 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Phase 3 Completed

1,209 enrolled 16 charts 1 FDA

Prostatic Neoplasms